Bank of Montreal
ANTX icon

Bank of Montreal’s AN2 Therapeutics ANTX Stock Holding History

Bank of Montreal’s Portfolio ANTX Stock Details ANTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-260,127
Closed -$890K – 3841
2026
Q1 		$890K Sell
260,127
-161,950
-38% -$334K ﹤0.01% 2094
2025
Q4 		$481K Hold
422,077
– – ﹤0.01% 2325
2025
Q3 		$536K Hold
422,077
– – ﹤0.01% 2235
2025
Q2 		$447K Hold
422,077
– – ﹤0.01% 2342
2025
Q1 		$574K Hold
422,077
– – ﹤0.01% 2110
2024
Q4 		$582K Buy
+422,077
New +$512K ﹤0.01% 2147

Other funds holding ANTX

VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SC
SummitTX Capital Fort Worth, Texas $3.89B AUM 55.94% 1-Year Est. Return

Bank of Montreal's ANTX Position: Q2 2026 in Review

Bank of Montreal sold out of AN2 Therapeutics (ANTX) in Q2 2026, closing a stake of 260,127 shares — an estimated $890K sold.

Bank of Montreal first reported a position in ANTX in Q4 2024 and held it in 6 quarters. The position peaked at $890K in Q1 2026. 59 funds tracked by Wall St. Rank hold ANTX as of Q2 2026.

  • Bank of Montreal reported no remaining AN2 Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Bank of Montreal sold 260,127 AN2 Therapeutics shares in Q2 2026, an estimated $890K.
  • Bank of Montreal first reported a position in AN2 Therapeutics in Q4 2024 and held it in 6 quarters.
  • Bank of Montreal's AN2 Therapeutics position peaked at $890K in Q1 2026.
  • 59 funds tracked by Wall St. Rank held AN2 Therapeutics as of Q2 2026.

Based on Bank of Montreal's 13F filing for Q2 2026, filed 12 Aug 2026.